targets glutamate and GABAA receptors (Miller, 2008, Johnson, 2010). Our results show that functional glutamate and GABAA receptors are expressed in iPS-derived neural cultures. Because the use of iPS cell technologies allows us to obtain neural cultures from individuals with different genotypes, we propose that these cells could be used as models to evaluate drug therapies and their adverse effects in the treatment of alcohol use disorders. While the use of iPS cells to model pathophysiology and to screen potential drug therapies is still in its early stages, further research can be expected to clarify the potential benefits and limitations of this approach.
